But really, how bad is it?

Some people have no side effects at all. It can vary. Sometimes side effects will hit with your second shot of a dose that you thought you were used to. They do fade away, for some faster than for others. These aren’t life-threatening side effects either. There are other Type 2 diabetes medications that have potential risks of hypoglycemia, diabetic ketoacidosis which lands a person in the hospital, or other scary things. 


The studies show that the GI adverse events eventually diminish. They stopped being frequently reported by trial participants after about the 20th week as shown in one of the SURPASS trial studies. Every research article has a similar phrase that says “side effects are mostly gastrointestinal and are dose-dependent and associated with dosage increases.”

Mounjaro may be less likely to make you feel barfy than Ozempic GLP-2RA drugs without the GIP receptor being involved. 

“Glucagon-like peptide 1 receptor (GLP-1R) agonists decrease body weight and improve glycemic control in obesity and diabetes. Patient compliance and maximal efficacy of GLP-1 therapeutics are limited by adverse side effects, including nausea and emesis. In three different species (i.e., mice, rats, and musk shrews), we show that glucose-dependent insulinotropic polypeptide receptor (GIPR) signaling blocks emesis and attenuates illness behaviors elicited by GLP-1R activation, while maintaining reduced food intake, body weight loss, and improved glucose tolerance. The area postrema and nucleus tractus solitarius (AP/NTS) of the hindbrain are required for food intake and body weight suppression by GLP-1R ligands and processing of emetic stimuli. Using single-nuclei RNA sequencing, we identified the cellular phenotypes of AP/NTS cells expressing GIPR and GLP-1R on distinct populations of inhibitory and excitatory neurons, with the greatest expression of GIPR in γ-aminobutyric acid-ergic neurons. This work suggests that combinatorial pharmaceutical targeting of GLP-1R and GIPR will increase efficacy in treating obesity and diabetes by reducing nausea and vomiting.”
From: GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist–Induced Nausea and Emesis in Preclinical Models

Diabetes, August 2021